For instance, in patients with breast cancer who are human epidermal growth factor receptor 2 (HER2) positive, Trastuzumab effectively suppresses tumor growth by binding to FcγRIIIa, thereby activating natural killer cells and macrophages and enhancing the ADCC response.[37] A deeper understanding of FcγR biology may pave the way for innovative strategies to modulate immune responses and enhance therapeutic efficacy in diverse clinical scenarios. Here, FCGR2A is linked to breast carcinoma.